• Privacy policy
  • T&C’s
  • About Us
    • FAQ
  • Contact us
  • Guest Content
  • TLE
  • News
  • Politics
  • Opinion
    • Elevenses
  • Business
  • Food
  • Travel
  • Property
  • JOBS
  • All
    • All Entertainment
    • Film
    • Sport
    • Tech/Auto
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
The London Economic
No Result
View All Result
Home Lifestyle Health

New Statins controversy as study compares risks and benefits

Researchers say the potential risks of taking the cholesterol-busting drugs might outweigh their benefits

Ben Gelblum by Ben Gelblum
2018-12-03 22:06
in Health, Science
Photo: PA

Photo: PA

FacebookTwitterLinkedinEmailWhatsapp

Statins may be over-prescribed, warns a new study.

Researchers say the potential risks of taking the cholesterol-busting drugs might outweigh their benefits.

Statins are among the world’s most commonly prescribed drugs, with more than 30 per cent of adults over the age of 40 being eligible for treatment.

They reduce levels of low-density lipoprotein – or ‘bad’ cholesterol – produced inside the liver.

High levels of bad cholesterol can lead to a hardening and narrowing of the arteries and cardiovascular disease (CVD), according to the NHS website.

Doctors prescribe statins to prevent the onset of CVD – the most common killer in Britain.

Most guidelines recommend statins as primary prevention for people without previous CVD when there is up to a 10 per cent chance of them developing it within ten-years.

But whether and how guideline developers weighed harms against benefits is often unclear.

German scientists found the potential risks of statins outweighed their benefits among people whose 10-year cardiovascular disease risk was between 7.5 and 10 per cent – as guideline currently recommend.

RelatedPosts

Personal Training Prices in London 2023

Alopecia Sufferers Increasingly Turning to Turkey for Hair Transplant Treatment

Beauty From Within: How Stem Cell Treatment Can Improve Your Skin

Can Crypto Trading Lead to Addiction

The figure was calculated using a computer model to examine the ‘benefits and harms’ of the drug.

But prescribing only for those at higher risk thresholds would mean denying millions of eligible people of the medicine.

University of Zurich researchers evaluated the ten-year CVD risk threshold, at which the benefits of statins outweighed the harms, with separate estimates for men and women of different ages.

The harms were consistently found to exceed the benefits until people were at substantially higher risk of developing CVD than the ten-year threshold recommended by current guidelines.

Among men aged 70 to 75, with no prior cardiovascular disease events, benefits only outweighed harms for those at more than 21 per cent risk of CVD over a ten-year period.

The study’s approach was developed by national Cancer Institute investigators whereby they projected disease and drug-related adverse events (myopathy, hepatic dysfunction, and incident diabetes) over time while accounting for competing mortality.

Study authors included a wide range of adverse events for statin therapy that were largely dismissed in other guidelines, according to the author of an accompanying Yale University School of Medicine editorial.

But the findings may help to inform decision-making for older adults who are more concerned about the harms of treatment.

Study lead author Dr Milo Puhan said: “Most guidelines recommend statins as primary prevention for people without previous cardiovascular disease when the 10-year risk for CVD exceeds 7.5 per cent to 10 per cent, but whether and how guideline developers weighed harms against benefits is often unclear.”

The findings were published in the journal Annals of Internal Medicine.

By Ben Gelblum and Laura Sharman

Previous Post

The Advantages of Repairing your Car’s Windshield

Next Post

Study warns chemicals in common household products cause earlier puberty in girls

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

More from TLE

Oxbridge dethroned as Scottish university named best in UK

Low nickel output amid rising output

Russell Brand accused of rape, sexual assaults and emotional abuse

MPs press GB News on Dan Wootton investigation

Truss: My economic plan would have saved taxpayers £35 billion

Sunak convenes Cabinet as he prepares to water down net zero plans

Britain is finally taking back control – by re-joining EU institutions

Quarter of UK universities offer food banks to students as cost of living soars

Truss tells Govt to slash benefits while claiming from £115k ex-PM allowance

Government LOSES bid to relax waterway pollution

JOBS

FIND MORE JOBS

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

Contact

Editorial enquiries, please contact: [email protected]

Commercial enquiries, please contact: [email protected]

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




-->